Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 37, Issue 6, 2010, Pages 591-615

  Pang, K Sandy ^a   Durk, Matthew R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Absorption, transport and excretion; Metabolite kinetics; Physiologically based pharmacokinetic (PBPK) modeling; Sequential metabolism

Indexed keywords

CODEINE; DRUG METABOLITE; ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; GENTISAMIDE; MORPHINE; MORPHINE 3 GLUCURONIDE; SALICYLAMIDE; TRICHLOROACETIC ACID; TRICHLOROETHYLENE; VINYLIDENE CHLORIDE;

AREA UNDER THE CURVE; BINDING KINETICS; COMPARTMENT MODEL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; INTERMETHOD COMPARISON; INTESTINE ABSORPTION; INTESTINE SECRETION; LIVER BLOOD FLOW; LIVER CLEARANCE; MATHEMATICAL MODEL; NONHUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; TOXICOKINETICS;

ABSORPTION; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; HUMANS; INTESTINES; LIVER; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; SUBSTRATE CYCLING;

EID: 79951774366     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9185-x     Document Type: Conference Paper

References (90)

1. Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136
2. Rodgers T, Rowland M (2007) Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918-933 (Pubitemid 46675393)
3. Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276 (Pubitemid 40904190)
4. Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257 (Pubitemid 43874439)
5. Dedrick RL, Forrester DD, Cannon JN, el-Dareer SM, Mellett LB (1973) Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. Biochem Pharmacol 22:2405-2417
6. Boxenbaum H, Ronfeld R (1983) Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768-R775 (Pubitemid 14219457)
7. Rowland M (1985) Physiologic pharmacokinetic models and interanimal species scaling. Pharmacol Ther 29:49-68 (Pubitemid 16160378)
8. Kawai R, Mathew D, Tanaka C, Rowland M (1998) Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 287:457-468 (Pubitemid 29133641)
9. Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908 (Pubitemid 36995260)
10. Nestorov I, Aarons L, Rowland M (1998) Quantitative structure- pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity. J Pharmacokinet Biopharm 26:521-545 (Pubitemid 29157781)
11. Rowland M, Balant L, Peck C (2004) Physiologically based pharmacokinetics in drug development, regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002. AAPS PharmSci 6:E6
12. Germani M, Crivori P, Rocchetti M, Burton PS, Wilson AG, Smith ME, Poggesi I (2007) Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur J Pharm Sci 31:190-201 (Pubitemid 46830884)
13. Lavé T, Parrott N, Grimm HP, Fleury A, Reddy M (2007) Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37:1295-1310 (Pubitemid 350035528)
14. Chiu WA, Barton HA, DeWoskin RS, Schlosser P, Thompson CM, Sonawane B, Lipscomb JC, Krishnan K (2007) Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J Appl Toxicol 27:218-237 (Pubitemid 46663416)
15. Clewell RA, Clewell HJ 3rd (2008) Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol 50:129-143 (Pubitemid 50013231)
16. Dobrev ID, Andersen ME, Yang RS (2002) In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane. Environ Health Perspect 110:1031-1039 (Pubitemid 35175046)
17. Gargas ML, Sweeney LM, Himmelstein MW, Pottenger LH, Bus JS, Holder JW (2008) Physiologically based pharmacokinetic modeling of chloroethane disposition in mice, rats, and women. Toxicol Sci 104:54-66 (Pubitemid 351859028)
18. Gargas ML, Tyler TR, Sweeney LM, Corley RA, Weitz KK, Mast TJ, Paustenbach DJ, Hays SM (2000) A toxicokinetic study of inhaled ethylene glycol ethyl ether acetate and validation of a physiologically based pharmacokinetic model for rat and human. Toxicol Appl Pharmacol 165:63-73 (Pubitemid 30346461)
19. Gargas ML, Tyler TR, Sweeney LM, Corley RA, Weitz KK, Mast TJ, Paustenbach DJ, Hays SM (2000) A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human. Toxicol Appl Pharmacol 165:53-62 (Pubitemid 30346460)
20. Sweeney LM, Andersen ME, Gargas ML (2004) Ethyl acrylate risk assessment with a hybrid computational fluid dynamics and physiologically based nasal dosimetry model. Toxicol Sci 79:394-403 (Pubitemid 38786896)
21. Edginton AN, Schmitt W, Voith B, Willmann S (2006) A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 45:683-704 (Pubitemid 43990570)
22. Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45:931-956 (Pubitemid 44299829)
23. Bjorkman S, Wada DR, Berling BM, Benoni G (2001) Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 90:1226-1241 (Pubitemid 32867972)
24. Harrison LI, Gibaldi M (1977) Physiologically based pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans. J Pharm Sci 66:1679-1683 (Pubitemid 8246673)
25. Tod M, Lagneau F, Jullien V, Mimoz O (2008) A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Application to amoxicillin-clavulanate. Pharm Res 25:1431-1439
26. Tsuji A, Nishide K, Minami H, Nakashima E, Terasaki T, Yamana T (1985) Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. Drug Metab Dispos 13:729-739 (Pubitemid 16198580)
27. Sugita O, Sawada Y, Sugiyama Y, Iga T, Hanano M (1982) Physiologically based pharmacokinetics of drug-drug interaction: a study of tolbutamide- sulfonamide interaction in rats. J Pharmacokinet Biopharm 10:297-316 (Pubitemid 12035889)
28. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662
29. Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 36:499-513 (Pubitemid 43890729)
30. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196
31. Atrakchi AH (2009) Interpretation and considerations on the safety evaluation of human drug metabolites. Chem Res Toxicol 22:1217-1220
32. Shitara Y, Hirano M, Sato H, Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236 (Pubitemid 39287802)
33. Isoherranen N, Hachad H, Yeung CK, Levy RH (2009) Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol 22:294-298
34. Baillie TA (2009) Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials. Chem Res Toxicol 22:263-266
35. Pang KS (2009) Safety testing of metabolites: expectations and outcomes. Chem Biol Interact 179:45-59
36. Pang KS, Morris ME, Sun H (2008) Formed and preformed metabolites: facts and comparisons. J Pharm Pharmacol 60:1247-1275
37. Pang KS, Gillette JR (1979) Sequential first-pass elimination of a metabolite derived from a precursor. J Pharmacokinet Biopharm 7:275-290 (Pubitemid 9225442)
38. Pang KS (1985) A review of metabolite kinetics. J Pharmacokinet Biopharm 13:633-662 (Pubitemid 16136868)
39. Pang KS, Kwan KC (1983) A commentary: methods and assumptions in the kinetic estimation of metabolite formation. Drug Metab Dispos 11:79-84 (Pubitemid 13113885)
40. Sun H, Pang KS (2010) Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 27:1237-1254
41. de Lannoy IA, Pang KS (1986) Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite. Drug Metab Dispos 14:513-520 (Pubitemid 16026711)
42. de Lannoy IA, Pang KS (1987) Effect of diffusional barriers on drug and metabolite kinetics. Drug Metab Dispos 15:51-58 (Pubitemid 17014506)
43. Pang KS, Cherry WF, Terrell JA, Ulm EH (1984) Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metab Dispos 12:309-313 (Pubitemid 15120549)
44. Tirona RG, Pang KS (1996) Sequestered endoplasmic reticulum space for sequential metabolism of salicylamide. Coupling of hydroxylation and glucuronidation. Drug Metab Dispos 24:821-833 (Pubitemid 26274738)
45. Tan E, Lu T, Pang KS (2001) Futile cycling of estrone sulfate and estrone in the recirculating perfused rat liver preparation. J Pharmacol Exp Ther 297:423-436 (Pubitemid 32242604)
46. Schwab AJ, Tao L, Yoshimura T, Simard A, Barker F, Pang KS (2001) Hepatic uptake and metabolism of benzoate: a multiple indicator dilution, perfused rat liver study. Am J Physiol Gastrointest Liver Physiol 280:G1124-G1136
47. Chen J, Pang KS (1997) Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations. J Pharmacol Exp Ther 280:24-31 (Pubitemid 27171383)
48. St-Pierre MV, Pang KS (1993) Kinetics of sequential metabolism. I. Formation and metabolism of oxazepam from nordiazepam and temazepam in the perfused murine liver. J Pharmacol Exp Ther 265:1429-1436 (Pubitemid 23321052)
49. Sun H, Pang KS (2009) Disparity in intestine disposition between formed and preformed metabolites and implications: a theoretical study. Drug Metab Dispos 37:187-202
50. Xu X, Pang KS (1989) Hepatic modeling of metabolite kinetics in sequential and parallel pathways: salicylamide and gentisamide metabolism in perfused rat liver. J Pharmacokinet Biopharm 17:645-671 (Pubitemid 20162868)
51. Cong D, Doherty M, Pang KS (2000) A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 28:224-235 (Pubitemid 30069008)
52. Doherty MM, Pang KS (2000) Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. Pharm Res 17:291-298 (Pubitemid 30225132)
53. Pang KS (2003) Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 31:1507-1519 (Pubitemid 37466919)
54. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684 (Pubitemid 47578116)
55. Tam D, Tirona RG, Pang KS (2003) Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 31:373-383 (Pubitemid 36378514)
56. Liu L, Pang KS (2006) An integrated approach to model hepatic drug clearance. Eur J Pharm Sci 29:215-230 (Pubitemid 44602411)
57. Abu-Zahra TN, Pang KS (2000) Effect of zonal transport and metabolism on hepatic removal: enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. Drug Metab Dispos 28:807-813 (Pubitemid 30470831)
58. Andersen ME, Birnbaum LS, Barton HA, Eklund CR (1997) Regional hepatic CYP1A1 and CYP1A2 induction with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. Toxicol Appl Pharmacol 144:145-155 (Pubitemid 27208346)
59. Pang KS, Xu X, Morris ME, Yuen V (1987) Kinetic modeling of conjugations in liver. Fed Proc 46:2439-2441
60. Baillie TA, Halpin RA, Matuszewski BK, Geer LA, Chavez-Eng CM, Dean D, Braun M, Doss G, Jones A, Marks T, Melillo D, Vyas KP (2001) Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques. Drug Metab Dispos 29:1614-1628 (Pubitemid 33111595)
61. Meffin PJ, Zilm DM, Veenendaal JR (1983) Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle. J Pharmacol Exp Ther 227:732-738 (Pubitemid 14215060)
62. Grubb NG, Rudy DW, Brater DC, Hall SD (1999) Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. Br J Clin Pharmacol 48:494-500 (Pubitemid 29454228)
63. Hansel SB, Morris ME (1996) Hepatic conjugation/deconjugation cycling pathways. Computer simulations examining the effect of Michaelis-Menten parameters, enzyme distribution patterns, and a diffusional barrier on metabolite disposition. J Pharmacokinet Biopharm 24:219-243 (Pubitemid 26300486)
64. Kauffman FC, Whittaker M, Anundi I, Thurman RG (1991) Futile cycling of a sulfate conjugate by isolated hepatocytes. Mol Pharmacol 39:414-420
65. Ratna S, Chiba M, Bandyopadhyay L, Pang KS (1993) Futile cycling between 4-methylumbellif- erone and its conjugates in perfused rat liver. Hepatology 17:838-853 (Pubitemid 23150094)
66. Xu X, Selick P, Pang KS (1993) Nonlinear protein binding and enzyme heterogeneity: effects on hepatic drug removal. J Pharmacokinet Biopharm 21:43-74 (Pubitemid 23261730)
67. Sun H, Zeng YY, Pang KS (2010) Interplay of phase II enzymes and transporters in futile cycling: influence of multidrug resistance-associated protein 2-mediated excretion of estradiol 17β-D-glucuronide and its 3-sulfate metabolite on net sulfation in perfused TR- and Wistar rat liver preparations. Drug Metab Dispos 38:769-780
68. Chen S, Fan J, Pang KS (2010) Physiologically-based pharmacokinetic (PBPK) models for the description of sequential metabolism of codeine to morphine and morphine 3-glucuronide in man and rat, AAPS Annual Meeting, New Orleans, LA, 2010; Abstract #R6395
69. Chiu WA, Okino MS, Evans MV (2009) Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol Appl Pharmacol 241:36-60
70. Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103-1127 (Pubitemid 13013622)
71. Verwei M, van Burgsteden JA, Krul CA, van de Sandt JJ, Freidig AP (2006) Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. Toxicol Lett 165:79-87 (Pubitemid 43867181)
72. Barton HA, Clewell HJ 3rd (2000) Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. Environ Health Perspect 108(Suppl 2):323-334 (Pubitemid 30420990)
73. Sweeney LM, Kirman CR, Gargas ML, Dugard PH (2009) Contribution of trichloroacetic acid to liver tumors observed in perchloroethylene (perc)-exposed mice. Toxicology 260:77-83
74. Yang RS, el-Masri HA, Thomas RS, Constan AA, Tessari JD (1995) The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. Toxicol Lett 79:193-200
75. Andersen ME, Clewell HJ 3rd, Gargas ML, Smith FA, Reitz RH (1987) Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205 (Pubitemid 17019104)
76. Clewell HJ, Gentry PR, Gearhart JM, Allen BC, Andersen ME (2001) Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci Total Environ 274:37-66 (Pubitemid 32591381)
77. Reitz RH, Gargas ML, Andersen ME, Provan WM, Green TL (1996) Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. Toxicol Appl Pharmacol 137:253-267 (Pubitemid 26130143)
78. Clewell HJ 3rd, Andersen ME, Wills RJ, Latriano L (1997) A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 36:S77-S85 (Pubitemid 27132004)
79. Frederick CB, Bush ML, Lomax LG, Black KA, Finch L, Kimbell JS, Morgan KT, Subramaniam RP, Morris JB, Ultman JS (1998) Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways. Toxicol Appl Pharmacol 152:211-231 (Pubitemid 28498690)
80. Frederick CB, Lomax LG, Black KA, Finch L, Scribner HE, Kimbell JS, Morgan KT, Subramaniam RP, Morris JB (2002) Use of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry comparisons of ester vapors. Toxicol Appl Pharmacol 183:23-40
81. Andersen ME, Sarangapani R, Frederick CB, Kimbell JS (1999) Dosimetric adjustment factors for methyl methacrylate derived from a steady-state analysis of a physiologically based clearance- extraction model. Inhal Toxicol 11:899-926 (Pubitemid 29523958)
82. Sarangapani R, Teeguarden JG, Cruzan G, Clewell HJ, Andersen ME (2002) Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans. Inhal Toxicol 14:789-834
83. Evans MV, Chiu WA, Okino MS, Caldwell JC (2009) Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly. Toxicol Appl Pharmacol 236:329-340
84. Sarangapani R, Teeguarden J, Andersen ME, Reitz RH, Plotzke KP (2003) Route-specific differences in distribution characteristics of octamethylcyclotetrasiloxane in rats: analysis using PBPK models. Toxicol Sci 71:41-52 (Pubitemid 36163704)
85. Corley RA, Bartels MJ, Carney EW, Weitz KK, Soelberg JJ, Gies RA, Thrall KD (2005) Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic acid, in rats and humans. Toxicol Sci 85:476-490 (Pubitemid 40614277)
86. McMullin TS, Hanneman WH, Cranmer BK, Tessari JD, Andersen ME (2007) Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. Toxicology 240:1-14 (Pubitemid 47445956)
87. Clewell RA, Kremer JJ, Williams CC, Campbell JL Jr, Andersen ME, Borghoff SJ (2008) Tissue exposures to free and glucuronidated monobutylyphthalate in the pregnant and fetal rat following exposure to di-n-butylphthalate: evaluation with a PBPK model. Toxicol Sci 103:241-259 (Pubitemid 351659597)
88. Sweeney LM, Thrall KD, Poet TS, Corley RA, Weber TJ, Locey BJ, Clarkson J, Sager S, Gargas ML (2008) Physiologically based pharmacokinetic modeling of 1,4-dioxane in rats, mice, and humans. Toxicol Sci 101:32-50 (Pubitemid 350239010)
89. Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD (2009) Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 37:1587-1597
90. Rietjens IM, Punt A, Schilter B, Scholz G, Delatour T, van Bladeren PJ (2010) In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment. Mol Nutr Food Res 54:195-207